Skip to main content
. 2018 Mar 7;9:335. doi: 10.3389/fimmu.2018.00335

Figure 2.

Figure 2

Distribution of AdHu5 and AdC68 neutralizing antibody (NAb) titers in positive samples from cancer patients in different clinical stages. NAb titers were stratified in the following tiers: low titer (≥20 and ≤160), medium titer (≥320 and ≤640), and high titer (≥1,280). For stage-I positive subjects, the AdHu5 NAb titers from low to high were 58.54, 34.15, and 7.32%, respectively, whereas the AdC68 NAb titers from low to high were 94.55, 5.45, and 0%, respectively; a significant difference existed between the AdHu5 NAb and AdC68 NAb titers among stage-I positive subjects (P < 0.01). For stage-II positive subjects, the AdHu5 NAb titers from low to high were 64.81, 29.63, and 5.56%, respectively, while all of the positive AdC68 NAb sample titers were lower or equal to 160. For stage-III positive subjects, the AdHu5 NAb titers from low to high were 61.45, 32.53, and 6.02%, respectively. However, most cancer patients exhibited low NAb titers against AdC68 (≥20 and ≤160, 94.12%), and a small fraction of cancer patients exhibited a medium level of AdC68 NAb titers (≥320 and ≤640, 5.88%). For stage-IV positive subjects, the AdHu5 NAb titers from low to high were 40.91, 45.45, and 13.64%, respectively, while the AdC68 NAb titers from low to high were 86.67, 13.33, and 0%, respectively; this was significantly different from AdHu5 (P < 0.05).